Bexsero (meningococcal group B vaccine) / GSK 
Welcome,         Profile    Billing    Logout  
 6 Diseases   29 Trials   29 Trials   518 News 
42 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bexsero (meningococcal group B vaccine) / GSK
2014-000126-38: Investigating the immune response to 4CMenB in infants(EUCLIDS)

Ongoing
4
160
Europe
Bexsero, Suspension for injection in pre-filled syringe, Bexsero
University of Oxford
This study aims to investigate gene expression following vaccination with 4CMenB and relate this to vaccine reactions and to immune response, Body processes [G] - Genetic Phenomena [G05]
 
 
2015-000817-32: Assessing responses to the booster dose of pneumococcal vaccine in children who had less than the standard number of doses as babies, as well as meningococcal B vaccine as babies.

Ongoing
4
200
Europe
Bexsero, Prevenar13, Infanrix-IPV, Menitorix, Injection, Bexsero, Prevenar13, Infanrix-IPV, Menitorix
University of Oxford, Department of Health (UK)
Immunological responses to vaccination in health y participants under reduced dose vaccine schedules, how well babies respond to different vaccine schedules, Body processes [G] - Immune system processes [G12]
 
 
2017-004609-42: Be on the TEAM: TEenagers Against Meningitis

Not yet recruiting
4
24000
Europe
Bexsero, Trumenba, Suspension for injection in pre-filled syringe, Solution for injection in pre-filled syringe, Bexsero, Trumenba
Clinical Trials and Research Governance (CTRG), University of Oxford, National Institute of Health Research, Pfizer Ltd
Oropharyngeal meningococcal carriage. Meningococci have the potential to cause invasive meningococcal disease. This study investigates the ability of Meningococcal B vaccines to reduce the carriage of meningococci., Bacterial colonisation of the mouth and throat with a germ called meningococcus. The ability of vaccines to reduce the rates of colonisation with this germ., Body processes [G] - Immune system processes [G12]
 
 
2018-003451-38: The 6-in-1 Vaccine Study

Not yet recruiting
4
240
Europe
INFANRIX-HEXA, Vaxelis (DTaP -HB-IPV-Hib), Bexsero, Prevenar 13, Menitorix, Rotarix, M-M-RVAXPRO, Priorix, Suspension for injection, Powder and solvent for solution for injection, Oral suspension, Powder and solvent for suspension for injection, , INFANRIX-HEXA, Vaxelis (DTaP -HB-IPV-Hib), Bexsero, Prevenar 13, Menitorix, Rotarix, M-M-RVAXPRO, Priorix
Clinical Trials and Research Governance (CTRG)
Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy., Compare the immunogenicity of the Haemophilus influenza type B (Hib) component of 6in1-IH (Infanrix-Hexa) and 6in1-V (Vaxelis) when co-administered with 4CMenB in the UK routine immunisation schedule., Body processes [G] - Immune system processes [G12]
 
 
2019-002829-29: Comparison of preventive treatements against bacterial STIs in PrEP users Comparaison de traitements préventifs des IST bactériennes chez les PrEPeurs

Not yet recruiting
4
720
Europe
Suspension for injection in pre-filled syringe, Tablet, Bexsero
INSERM ANRS, ANRS
MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis) HSH prenant la PrEP (Prophylaxie Pré-Exposition) depuis au moins 6 mois, MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis) HSH prenant la PrEP (Prophylaxie Pré-Exposition) depuis au moins 6 mois, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2020-000863-22: Safety and immune respons following meningococcal and pneumococcal vaccination among adult people living with HIV.

Not yet recruiting
4
55
Europe
Prevenar-13, Pneumovax, Menveo, Bexsero
Thomas Benfield, Hvidovre Hospital, Department of Infectious Diseases
Immunogenicity following pneumococcal and meningococcal vaccination among people living with HIV, Immune response following pneumococcal and meningococcal vaccination among people living with HIV, Body processes [G] - Immune system processes [G12]
 
 
2019-002585-12: Study to Assess the Immune Response and the Safety Profile of DTaP-IPVHB- PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian Infants Studio per valutare la risposta immunitaria e il profilo di sicurezza del vaccino combinato DTaP-IPVHB- PRP ~ T somministrato in concomitanza o in sequenza con il vaccino 4CMenB in infanti italiani

Ongoing
4
396
Europe
NA, [NA], Suspension for injection, Suspension for injection in pre-filled syringe, Hexyon sospensione iniettabile - vaccino coniugato (adsorbito) contro difterite, tetano, pertosse (componente acellulare), epatite B (rDNA), poliomielite (inattivato) ed Haemophilus influenzae di tipo b, Bexsero sospensione iniettabile in siringa preriempita - Vaccino contro il meningococco di gruppo B (rDNA, componente, adsorbito), Prevenar 13 sospensione iniettabile - Vaccino pneumococcico polisaccaridico coniugato (13 valente adsorbito)
SANOFI PASTEUR, Sanofi Pasteur, Sanofi Pasteur
Haemophilus influenzae type b immunisation Immunizzazione Haemophilus influenzae di tipo B, Active immunization against diphtheriae, tetanus, pertussis, hepatitis B, poliomyelitis & invasive infections caused by Haemophilus influenzae type b Immunizzazione attiva contro difterite, tetano, pertosse, epatite B, poliomielite e infezioni invasive causate da Haemophilus influenzae di tipo b, Diseases [C] - Virus Diseases [C02]
 
 
2017-004732-11: Meningococcal B Booster Vaccine in Young People

Not yet recruiting
4
117
Europe
Bexsero, Suspension for injection in pre-filled syringe, Bexsero
University of Oxford, Meningitis Research Foundation
Meningococcus group B disease, which can cause a variety of symptoms. The most serious of these are meningitis, and septicaemia (also known as blood poisoning)., Meningitis group B, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT03880669: The 6-in-1 Vaccine Study

Not yet recruiting
4
240
Europe
Infanrix hexa or Vaxelis
University of Oxford, MCM Vaccines B.V.
Vaccination; Infection
10/21
04/22
ACTRN12619001478101: MenGO: Does the licensed meningococcal vaccine Bexsero® provide cross- protection against gonorrhoea?

Completed
4
130
 
Gold Coast Hospital and Health Service , Gold Coast Hospital Foundation, Gold Coast Hospital and Health Service
Gonorrhoea infection, Meningococcal B vaccine
 
 
2023-000764-58: A study on the immune response and safety of a vaccine against Neisseria meningitidis serogroup B infection in healthy infants from 2 months of age

Not yet recruiting
4
50
RoW
Suspension for injection in pre-filled syringe, Bexsero Prefilled Syringe
GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals SA
Healthy volunteers (active immunization of infants against invasive meningococcal disease (IMD) due to N. meningitidis serogroup B infection)., N. meningitidis serogroup B is the most common cause of bacterial meningitis and septicaemia., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
Vaxxygender, NCT06832514: Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

Recruiting
4
250
Europe
Serogroup B meningococal vaccine, Four component meningococcal serogroup B vaccine, 4CMenB, Bexsero
University Ghent, University Hospital, Ghent, Centre for Vaccinology - CEVAC
Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response, Vaccination
12/25
12/25
MENPI, NCT04875819 / 2020-000863-22: Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

Recruiting
4
55
Europe
Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, Menveo® and Bexsero®, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine, Prevenar13® and Pneumovax23®
Thomas Benfield, Hvidovre Hospital, Department of Infectious Diseases
Hiv, Meningococcal Infections, Pneumococcal Infections
12/26
12/26
2017-004520-30: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Concomitantly with Routine Pediatric Vaccines in the UK.

Not yet recruiting
3
700
Europe
MenACYW Conjugate Vaccine, Bexsero, 395, Solution for injection, Suspension for injection in pre-filled syringe, BEXSERO (Meningococcal group B Vaccine (rDNA, component, adsorbed))
Sanofi Pasteur, Sanofi Pasteur
Active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)., Invasive meningogoccal disease (IMD), Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2019-000924-17: Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies among patients with asplenia Essai multicentrique, randomisé de phase III, évaluant l'immunogénicité et la tolérance de trois stratégies vaccinales contre le méningocoque B chez des patients présentant une asplénie

Not yet recruiting
3
84
Europe
Solution for injection, Bexsero®, Trumenba®
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, DGOS
asplenic patients at risk for invasive meningococcal disease Patients splénectomisés à risque d'infection à meningocoque B, asplenic patients patients splénectomisés, Body processes [G] - Immune system processes [G12]
 
 
2020-004385-19: Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria

Ongoing
3
165
Europe
iptacopan, LNP023, Capsule, hard, PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml, ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, Nimenrix, HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Paroxysmal Nocturnal Hemoglobinuria (PNH), Blood disorder, Diseases [C] - Immune System Diseases [C20]
 
 
MET52, NCT03632720: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Completed
3
788
Europe
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, MenACYW Conjugate vaccine, Meningococcal group B vaccine, Bexsero®, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine, Infanrix hexa®, Human rotavirus RIX4414 strain vaccine, Rotarix®, Pneumococcal 13-valent polysaccharide conjugate vaccine, Prevenar 13®
Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
12/22
12/22
DOXYVAC, NCT04597424: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)

Completed
3
556
Europe
Experimental: doxycycline, Bexsero® vaccine
ANRS, Emerging Infectious Diseases
Unsafe Sex, Risk-Taking
02/23
04/24
MenABCWY – 019, NCT04707391 / 2019-004982-42: Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Completed
3
1250
Canada, US, RoW
MenABCWY vaccine, Placebo, MenACWY vaccine, Menveo, MenB vaccine, Bexsero
GlaxoSmithKline
Meningitis, Meningococcal
05/23
09/23
2022-000460-21: Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Seguridad y eficacia de ALXN1720 en adultos con miastenia gravis generalizada.

Not yet recruiting
3
200
Europe
Bexsero, na, Menveo, Ciprofloxacino normon 500mg, Eritromicina normon 500mg, Ciprofloxacina, Penilevel 500mg, ALXN1720, Concentrate for solution for injection, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, Menveo, Ciprofloxacino cinfa 500mg- cn 6970157, Ciprofloxacino normon 500mg -cn 6956212, Eritromicina normon 500mg – cn 6940167, Amoxicillina Almus 500, Bexsero, Ciprofloxacino teva 500mg – cn 6944967, Penilevel 500mg- cn 7135050
Alexion Pharmaceuticals, Inc, ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals, Inc, Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04318548 / 2016-003722-16: Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Completed
3
945
Europe, US
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Bexsero, Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Menveo, Placebo, NaCl, saline solution
GlaxoSmithKline
Infections, Meningococcal
11/23
11/23
NCT06446752: BIYELA - Bexsero Immunisation in Young Women in Africa

Recruiting
3
1100
RoW
Bexsero, 4MenB-4C, Placebo, Saline
University of Washington, Bill and Melinda Gates Foundation, University of Witwatersrand, South Africa
Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus, Gonorrhea of Cervix
10/26
01/27
NCT03621670 / 2016-003268-37: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed
3
1196
Europe, US
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
GlaxoSmithKline
Infections, Meningococcal
12/24
12/24
GoGoVax, NCT04415424: Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men

Active, not recruiting
3
650
RoW
4CMenB vaccine, Bexsero®, Placebo
Kirby Institute, Griffith University
Neisseria Gonorrheae Infection
06/25
10/25
NCT05766904: Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections

Active, not recruiting
3
150
RoW
4CMenB vaccine, Bexsero, Placebo
Chinese University of Hong Kong
Gonorrhea, Sexually Transmitted Infection
09/25
12/25
SPLEMENGO, NCT04166656: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
3
84
Europe
Trumenba®, Bexsero®
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, Innovative clinical research in vaccinologie (I-REIVAC), Institut Pasteur
Splenectomy
09/28
10/28
ACTRN12623000738628: VIRGo – Vaccine-induced Immune Responses against Gonorrhoea: A study to investigate immune response induced by the 4CMenB vaccine against gonorrhoea

Not yet recruiting
2/3
60
 
Gold Coast University Hospital, National Health and Medical Research Council
gonorrhoea
 
 
2017-000889-29: Study on efficacy and safety of LNP023 in C3 glomerulopathy patients transplanted and not transplanted

Not yet recruiting
2
27
Europe
NA, Bexsero, MENVEO, PNEUMOVAX, Vaccino Haemophilus influenzae di tipo b coniugato al tossoide tetanico, LNP023 hydrochloride, Capsule, hard, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, PNEUMOVAX, ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML
Novartis Pharma AG, Novartis Farmacéutica, S.A., NOVARTIS PHARMA AG, Novartis Pharma AG
C3 glomerulopathy, Kidney disorder, Diseases [C] - Immune System Diseases [C20]
 
 
NCT04722003: Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Completed
2
52
US
Meningococcal Group B Vaccine, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Gonorrhoea
10/23
10/23
NCT05082285 / 2021-001367-24: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Active, not recruiting
2
724
Europe, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, MenABCWY-1Gen vaccine, MenB vaccine, Bexsero, MenACWY-TT vaccine, Nimenrix
GlaxoSmithKline
Infections, Meningococcal
03/25
03/25
NCT06025487: Meningococcal B Vaccine in Patients with Asplenia

Recruiting
2
80
Europe
Bexsero
Medical University of Vienna
Splenectomy; Status
12/25
12/25
NCT04350138: Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

Active, not recruiting
2
2606
US, RoW
Meningococcal Group B Vaccine, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Gonococcal Infection
02/26
02/26
NCT05294588: Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Recruiting
2
140
US
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Bexsero, 4-component Neisseria meningitidis group B vaccine, 4CMenB, Influenza Vaccine, Flulaval, Tetanus-diptheria Vaccine, TDVAX
University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID)
Gonorrhea Male
02/28
02/28
NCT06128733: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Active, not recruiting
1/2
1220
US
Pentavalent Meningococcal ABCYW vaccine, MenPenta, MenACYW conjugate vaccine, MenQuadFi®, Meningococcal group B vaccine, Bexsero®, Trumenba®, Sanofi MenB, Menveo®, Placebo, MenABCYW conjugate vaccine, PENBRAYATM
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
06/25
06/25
2023-000924-13: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Not yet recruiting
1/2
1120
US
MenQuadfi, Bexsero, Trumenba, Menveo, 554, Suspension for injection, Solution for injection in vial, Suspension for injection in pre-filled syringe, Powder and solvent for solution for injection, MenQuadfi, Bexsero, Trumenba, MENVEO
Sanofi Pasteur Inc., Sanofi Pasteur Inc.
Bacterial infections and mycoses, Bacterial infections and mycoses, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT04886154 / 2020-004741-37: A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Completed
1/2
1440
Europe, US, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, NaCl, saline solution, MenB vaccine, GSK's meningococcal group B vaccine, Bexsero, MenACWY vaccine, GSK's combined meningococcal groups A, C, Y and W-135 conjugate vaccine, Menveo
GlaxoSmithKline
Infections, Meningococcal
02/24
02/24
NCT06647407: Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Recruiting
1/2
750
RoW
Pentavalent Meningococcal ABCYW vaccine, MenPenta, MenACYW conjugate vaccine, MenQuadfi®, Nimenrix®, Meningococcal group B vaccine, Bexsero®, Paracetamol, DTap-HepB-IPV-Hib vaccine, Hexyon®, Vaxelis®, Infanrix hexa®, Rotavirus vaccine, RotaTeq® Rotarix®, Pneumococcal 13-valent conjugate vaccine, Prevnar 13®
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunization, Healthy Volunteers
04/27
05/27
NCT06033261: A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Active, not recruiting
1/2
365
US
mRNA-1608, BEXSERO
ModernaTX, Inc.
Genital Herpes
04/25
04/25
2023-000765-14: Post marketing surveillance to collect safety information after vaccination with Bexsero administered in routine care and according to prescribing information in Korea.

Not yet recruiting
1
600
RoW
Bexsero Prefilled Syringe
GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals SA
The study will collect real-world post-vaccination adverse events., Not applicable
 
 
NCT04825223: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Terminated
1
576
US
Multicomponent Meningococcal B Vaccine, Trumenba®, Meningococcal Group B Vaccine MenB, MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Bexsero®, Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine, MenQuadfi™
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
07/22
07/22
NCT04239430: Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

Recruiting
N/A
55
Europe
Serum Bactericidal Assays
St George's, University of London, Public Health England
HIV/AIDS, Meningococcal Disease
04/22
04/22
NCT04398849: Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)

Recruiting
N/A
7100
RoW
Licenced 4CMenB Vaccine
University of Adelaide, The University of New South Wales, Menzies School of Health Research, University of Sydney, The University of Western Australia, Northern Territory Government of Australia, SA Health, The University of Queensland
Gonorrhea, Meningococcal Disease
12/24
12/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bexsero (meningococcal group B vaccine) / GSK
2014-000126-38: Investigating the immune response to 4CMenB in infants(EUCLIDS)

Ongoing
4
160
Europe
Bexsero, Suspension for injection in pre-filled syringe, Bexsero
University of Oxford
This study aims to investigate gene expression following vaccination with 4CMenB and relate this to vaccine reactions and to immune response, Body processes [G] - Genetic Phenomena [G05]
 
 
2015-000817-32: Assessing responses to the booster dose of pneumococcal vaccine in children who had less than the standard number of doses as babies, as well as meningococcal B vaccine as babies.

Ongoing
4
200
Europe
Bexsero, Prevenar13, Infanrix-IPV, Menitorix, Injection, Bexsero, Prevenar13, Infanrix-IPV, Menitorix
University of Oxford, Department of Health (UK)
Immunological responses to vaccination in health y participants under reduced dose vaccine schedules, how well babies respond to different vaccine schedules, Body processes [G] - Immune system processes [G12]
 
 
2017-004609-42: Be on the TEAM: TEenagers Against Meningitis

Not yet recruiting
4
24000
Europe
Bexsero, Trumenba, Suspension for injection in pre-filled syringe, Solution for injection in pre-filled syringe, Bexsero, Trumenba
Clinical Trials and Research Governance (CTRG), University of Oxford, National Institute of Health Research, Pfizer Ltd
Oropharyngeal meningococcal carriage. Meningococci have the potential to cause invasive meningococcal disease. This study investigates the ability of Meningococcal B vaccines to reduce the carriage of meningococci., Bacterial colonisation of the mouth and throat with a germ called meningococcus. The ability of vaccines to reduce the rates of colonisation with this germ., Body processes [G] - Immune system processes [G12]
 
 
2018-003451-38: The 6-in-1 Vaccine Study

Not yet recruiting
4
240
Europe
INFANRIX-HEXA, Vaxelis (DTaP -HB-IPV-Hib), Bexsero, Prevenar 13, Menitorix, Rotarix, M-M-RVAXPRO, Priorix, Suspension for injection, Powder and solvent for solution for injection, Oral suspension, Powder and solvent for suspension for injection, , INFANRIX-HEXA, Vaxelis (DTaP -HB-IPV-Hib), Bexsero, Prevenar 13, Menitorix, Rotarix, M-M-RVAXPRO, Priorix
Clinical Trials and Research Governance (CTRG)
Immunogenicity and reactogenicity of concomitantly administered hexavalent and group B meningococcal vaccines in infancy., Compare the immunogenicity of the Haemophilus influenza type B (Hib) component of 6in1-IH (Infanrix-Hexa) and 6in1-V (Vaxelis) when co-administered with 4CMenB in the UK routine immunisation schedule., Body processes [G] - Immune system processes [G12]
 
 
2019-002829-29: Comparison of preventive treatements against bacterial STIs in PrEP users Comparaison de traitements préventifs des IST bactériennes chez les PrEPeurs

Not yet recruiting
4
720
Europe
Suspension for injection in pre-filled syringe, Tablet, Bexsero
INSERM ANRS, ANRS
MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis) HSH prenant la PrEP (Prophylaxie Pré-Exposition) depuis au moins 6 mois, MSM with at least 6-month experience with PrEP (Pre-Exposure Prophylaxis) HSH prenant la PrEP (Prophylaxie Pré-Exposition) depuis au moins 6 mois, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2020-000863-22: Safety and immune respons following meningococcal and pneumococcal vaccination among adult people living with HIV.

Not yet recruiting
4
55
Europe
Prevenar-13, Pneumovax, Menveo, Bexsero
Thomas Benfield, Hvidovre Hospital, Department of Infectious Diseases
Immunogenicity following pneumococcal and meningococcal vaccination among people living with HIV, Immune response following pneumococcal and meningococcal vaccination among people living with HIV, Body processes [G] - Immune system processes [G12]
 
 
2019-002585-12: Study to Assess the Immune Response and the Safety Profile of DTaP-IPVHB- PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian Infants Studio per valutare la risposta immunitaria e il profilo di sicurezza del vaccino combinato DTaP-IPVHB- PRP ~ T somministrato in concomitanza o in sequenza con il vaccino 4CMenB in infanti italiani

Ongoing
4
396
Europe
NA, [NA], Suspension for injection, Suspension for injection in pre-filled syringe, Hexyon sospensione iniettabile - vaccino coniugato (adsorbito) contro difterite, tetano, pertosse (componente acellulare), epatite B (rDNA), poliomielite (inattivato) ed Haemophilus influenzae di tipo b, Bexsero sospensione iniettabile in siringa preriempita - Vaccino contro il meningococco di gruppo B (rDNA, componente, adsorbito), Prevenar 13 sospensione iniettabile - Vaccino pneumococcico polisaccaridico coniugato (13 valente adsorbito)
SANOFI PASTEUR, Sanofi Pasteur, Sanofi Pasteur
Haemophilus influenzae type b immunisation Immunizzazione Haemophilus influenzae di tipo B, Active immunization against diphtheriae, tetanus, pertussis, hepatitis B, poliomyelitis & invasive infections caused by Haemophilus influenzae type b Immunizzazione attiva contro difterite, tetano, pertosse, epatite B, poliomielite e infezioni invasive causate da Haemophilus influenzae di tipo b, Diseases [C] - Virus Diseases [C02]
 
 
2017-004732-11: Meningococcal B Booster Vaccine in Young People

Not yet recruiting
4
117
Europe
Bexsero, Suspension for injection in pre-filled syringe, Bexsero
University of Oxford, Meningitis Research Foundation
Meningococcus group B disease, which can cause a variety of symptoms. The most serious of these are meningitis, and septicaemia (also known as blood poisoning)., Meningitis group B, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT03880669: The 6-in-1 Vaccine Study

Not yet recruiting
4
240
Europe
Infanrix hexa or Vaxelis
University of Oxford, MCM Vaccines B.V.
Vaccination; Infection
10/21
04/22
ACTRN12619001478101: MenGO: Does the licensed meningococcal vaccine Bexsero® provide cross- protection against gonorrhoea?

Completed
4
130
 
Gold Coast Hospital and Health Service , Gold Coast Hospital Foundation, Gold Coast Hospital and Health Service
Gonorrhoea infection, Meningococcal B vaccine
 
 
2023-000764-58: A study on the immune response and safety of a vaccine against Neisseria meningitidis serogroup B infection in healthy infants from 2 months of age

Not yet recruiting
4
50
RoW
Suspension for injection in pre-filled syringe, Bexsero Prefilled Syringe
GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals SA
Healthy volunteers (active immunization of infants against invasive meningococcal disease (IMD) due to N. meningitidis serogroup B infection)., N. meningitidis serogroup B is the most common cause of bacterial meningitis and septicaemia., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
Vaxxygender, NCT06832514: Investigating Gender and Sex Differences in Immune Responses Through Vaccination of Transgender and Cisgender Persons

Recruiting
4
250
Europe
Serogroup B meningococal vaccine, Four component meningococcal serogroup B vaccine, 4CMenB, Bexsero
University Ghent, University Hospital, Ghent, Centre for Vaccinology - CEVAC
Meningococcal Meningitis, Serogroup B, Transgender Persons, Sex Differences in Immune Response, Vaccination
12/25
12/25
MENPI, NCT04875819 / 2020-000863-22: Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV

Recruiting
4
55
Europe
Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, Menveo® and Bexsero®, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine, Prevenar13® and Pneumovax23®
Thomas Benfield, Hvidovre Hospital, Department of Infectious Diseases
Hiv, Meningococcal Infections, Pneumococcal Infections
12/26
12/26
2017-004520-30: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Concomitantly with Routine Pediatric Vaccines in the UK.

Not yet recruiting
3
700
Europe
MenACYW Conjugate Vaccine, Bexsero, 395, Solution for injection, Suspension for injection in pre-filled syringe, BEXSERO (Meningococcal group B Vaccine (rDNA, component, adsorbed))
Sanofi Pasteur, Sanofi Pasteur
Active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W)., Invasive meningogoccal disease (IMD), Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2019-000924-17: Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies among patients with asplenia Essai multicentrique, randomisé de phase III, évaluant l'immunogénicité et la tolérance de trois stratégies vaccinales contre le méningocoque B chez des patients présentant une asplénie

Not yet recruiting
3
84
Europe
Solution for injection, Bexsero®, Trumenba®
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, DGOS
asplenic patients at risk for invasive meningococcal disease Patients splénectomisés à risque d'infection à meningocoque B, asplenic patients patients splénectomisés, Body processes [G] - Immune system processes [G12]
 
 
2020-004385-19: Long-term safety and tolerability of iptacopan in patients with Paroxysmal Nocturnal Hemoglobinuria

Ongoing
3
165
Europe
iptacopan, LNP023, Capsule, hard, PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml, ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, Nimenrix, HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
Novartis Pharma AG, NOVARTIS PHARMA AG, Novartis Farmacéutica, S.A., Novartis Pharma AG
Paroxysmal Nocturnal Hemoglobinuria (PNH), Blood disorder, Diseases [C] - Immune System Diseases [C20]
 
 
MET52, NCT03632720: Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom

Completed
3
788
Europe
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine, MenACYW Conjugate vaccine, Meningococcal group B vaccine, Bexsero®, Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine, Infanrix hexa®, Human rotavirus RIX4414 strain vaccine, Rotarix®, Pneumococcal 13-valent polysaccharide conjugate vaccine, Prevenar 13®
Sanofi Pasteur, a Sanofi Company
Healthy Volunteers (Meningococcal Infection)
12/22
12/22
DOXYVAC, NCT04597424: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)

Completed
3
556
Europe
Experimental: doxycycline, Bexsero® vaccine
ANRS, Emerging Infectious Diseases
Unsafe Sex, Risk-Taking
02/23
04/24
MenABCWY – 019, NCT04707391 / 2019-004982-42: Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

Completed
3
1250
Canada, US, RoW
MenABCWY vaccine, Placebo, MenACWY vaccine, Menveo, MenB vaccine, Bexsero
GlaxoSmithKline
Meningitis, Meningococcal
05/23
09/23
2022-000460-21: Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Seguridad y eficacia de ALXN1720 en adultos con miastenia gravis generalizada.

Not yet recruiting
3
200
Europe
Bexsero, na, Menveo, Ciprofloxacino normon 500mg, Eritromicina normon 500mg, Ciprofloxacina, Penilevel 500mg, ALXN1720, Concentrate for solution for injection, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, Menveo, Ciprofloxacino cinfa 500mg- cn 6970157, Ciprofloxacino normon 500mg -cn 6956212, Eritromicina normon 500mg – cn 6940167, Amoxicillina Almus 500, Bexsero, Ciprofloxacino teva 500mg – cn 6944967, Penilevel 500mg- cn 7135050
Alexion Pharmaceuticals, Inc, ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals, Inc, Alexion Pharmaceuticals, Inc.
Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Generalized Myasthenia Gravis Miastenia Gravis Generalizada, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT04318548 / 2016-003722-16: Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

Completed
3
945
Europe, US
Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Bexsero, Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid), Menveo, Placebo, NaCl, saline solution
GlaxoSmithKline
Infections, Meningococcal
11/23
11/23
NCT06446752: BIYELA - Bexsero Immunisation in Young Women in Africa

Recruiting
3
1100
RoW
Bexsero, 4MenB-4C, Placebo, Saline
University of Washington, Bill and Melinda Gates Foundation, University of Witwatersrand, South Africa
Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus, Gonorrhea of Cervix
10/26
01/27
NCT03621670 / 2016-003268-37: Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed
3
1196
Europe, US
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
GlaxoSmithKline
Infections, Meningococcal
12/24
12/24
GoGoVax, NCT04415424: Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men

Active, not recruiting
3
650
RoW
4CMenB vaccine, Bexsero®, Placebo
Kirby Institute, Griffith University
Neisseria Gonorrheae Infection
06/25
10/25
NCT05766904: Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections

Active, not recruiting
3
150
RoW
4CMenB vaccine, Bexsero, Placebo
Chinese University of Hong Kong
Gonorrhea, Sexually Transmitted Infection
09/25
12/25
SPLEMENGO, NCT04166656: Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting
3
84
Europe
Trumenba®, Bexsero®
Assistance Publique - Hôpitaux de Paris, EUCLID Clinical Trial Platform, Recherche Clinique Paris Descartes Necker Cochin Sainte Anne, CIC 1417 Cochin-Pasteur, Innovative clinical research in vaccinologie (I-REIVAC), Institut Pasteur
Splenectomy
09/28
10/28
ACTRN12623000738628: VIRGo – Vaccine-induced Immune Responses against Gonorrhoea: A study to investigate immune response induced by the 4CMenB vaccine against gonorrhoea

Not yet recruiting
2/3
60
 
Gold Coast University Hospital, National Health and Medical Research Council
gonorrhoea
 
 
2017-000889-29: Study on efficacy and safety of LNP023 in C3 glomerulopathy patients transplanted and not transplanted

Not yet recruiting
2
27
Europe
NA, Bexsero, MENVEO, PNEUMOVAX, Vaccino Haemophilus influenzae di tipo b coniugato al tossoide tetanico, LNP023 hydrochloride, Capsule, hard, BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO, MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC, PNEUMOVAX, ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML
Novartis Pharma AG, Novartis Farmacéutica, S.A., NOVARTIS PHARMA AG, Novartis Pharma AG
C3 glomerulopathy, Kidney disorder, Diseases [C] - Immune System Diseases [C20]
 
 
NCT04722003: Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Completed
2
52
US
Meningococcal Group B Vaccine, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Gonorrhoea
10/23
10/23
NCT05082285 / 2021-001367-24: A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants

Active, not recruiting
2
724
Europe, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, MenABCWY-1Gen vaccine, MenB vaccine, Bexsero, MenACWY-TT vaccine, Nimenrix
GlaxoSmithKline
Infections, Meningococcal
03/25
03/25
NCT06025487: Meningococcal B Vaccine in Patients with Asplenia

Recruiting
2
80
Europe
Bexsero
Medical University of Vienna
Splenectomy; Status
12/25
12/25
NCT04350138: Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection

Active, not recruiting
2
2606
US, RoW
Meningococcal Group B Vaccine, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Gonococcal Infection
02/26
02/26
NCT05294588: Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Recruiting
2
140
US
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Bexsero, 4-component Neisseria meningitidis group B vaccine, 4CMenB, Influenza Vaccine, Flulaval, Tetanus-diptheria Vaccine, TDVAX
University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID)
Gonorrhea Male
02/28
02/28
NCT06128733: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Active, not recruiting
1/2
1220
US
Pentavalent Meningococcal ABCYW vaccine, MenPenta, MenACYW conjugate vaccine, MenQuadFi®, Meningococcal group B vaccine, Bexsero®, Trumenba®, Sanofi MenB, Menveo®, Placebo, MenABCYW conjugate vaccine, PENBRAYATM
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
06/25
06/25
2023-000924-13: Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Not yet recruiting
1/2
1120
US
MenQuadfi, Bexsero, Trumenba, Menveo, 554, Suspension for injection, Solution for injection in vial, Suspension for injection in pre-filled syringe, Powder and solvent for solution for injection, MenQuadfi, Bexsero, Trumenba, MENVEO
Sanofi Pasteur Inc., Sanofi Pasteur Inc.
Bacterial infections and mycoses, Bacterial infections and mycoses, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
NCT04886154 / 2020-004741-37: A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Completed
1/2
1440
Europe, US, RoW
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, NaCl, saline solution, MenB vaccine, GSK's meningococcal group B vaccine, Bexsero, MenACWY vaccine, GSK's combined meningococcal groups A, C, Y and W-135 conjugate vaccine, Menveo
GlaxoSmithKline
Infections, Meningococcal
02/24
02/24
NCT06647407: Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants

Recruiting
1/2
750
RoW
Pentavalent Meningococcal ABCYW vaccine, MenPenta, MenACYW conjugate vaccine, MenQuadfi®, Nimenrix®, Meningococcal group B vaccine, Bexsero®, Paracetamol, DTap-HepB-IPV-Hib vaccine, Hexyon®, Vaxelis®, Infanrix hexa®, Rotavirus vaccine, RotaTeq® Rotarix®, Pneumococcal 13-valent conjugate vaccine, Prevnar 13®
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunization, Healthy Volunteers
04/27
05/27
NCT06033261: A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Active, not recruiting
1/2
365
US
mRNA-1608, BEXSERO
ModernaTX, Inc.
Genital Herpes
04/25
04/25
2023-000765-14: Post marketing surveillance to collect safety information after vaccination with Bexsero administered in routine care and according to prescribing information in Korea.

Not yet recruiting
1
600
RoW
Bexsero Prefilled Syringe
GlaxoSmithKline Biologicals SA, GlaxoSmithKline Biologicals SA
The study will collect real-world post-vaccination adverse events., Not applicable
 
 
NCT04825223: Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Terminated
1
576
US
Multicomponent Meningococcal B Vaccine, Trumenba®, Meningococcal Group B Vaccine MenB, MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Bexsero®, Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine, MenQuadfi™
Sanofi Pasteur, a Sanofi Company
Meningococcal Immunisation, Healthy Volunteers
07/22
07/22
NCT04239430: Propositive (Protecting Positive People From Meningococcal Infection) Follow-up Study

Recruiting
N/A
55
Europe
Serum Bactericidal Assays
St George's, University of London, Public Health England
HIV/AIDS, Meningococcal Disease
04/22
04/22
NCT04398849: Immunisation for Adolescents Against Serious Communicable Diseases (B Part of it NT)

Recruiting
N/A
7100
RoW
Licenced 4CMenB Vaccine
University of Adelaide, The University of New South Wales, Menzies School of Health Research, University of Sydney, The University of Western Australia, Northern Territory Government of Australia, SA Health, The University of Queensland
Gonorrhea, Meningococcal Disease
12/24
12/24

Download Options